动脉粥样硬化,一种慢性和进行性疾病,其特征是炎症细胞和脂质在动脉壁内积聚,仍然是全球心血管疾病的主要原因。尽管在治疗动脉粥样硬化的药物治疗策略方面取得了相当大的进步,对于动脉粥样硬化,仍需要更有效的治疗方案.在这种追求中,β-环糊精(β-CD)作为一种有前途的治疗剂的出现为靶向动脉粥样硬化的药物递送提供了一种新的治疗方法。β-CD的疏水腔有利于其作为载体的作用,能够将各种治疗化合物封装和递送到脉管系统内受影响的部位。值得注意的是,基于β-CD的纳米组装体具有降低胆固醇水平的能力,减轻炎症,溶解疏水性药物并将药物输送到受影响的组织,使这些纳米组件有希望的候选动脉粥样硬化的管理。这篇综述集中在三大类基于β-CD的纳米组装体,包括基于β-CD的衍生物,基于β-CD/聚合物共轭物和基于聚合物β-CD的纳米组装体,强调各种配方和组装方法,以改善药物输送和治疗效果。这些基于β-CD的纳米组装体表现出多种治疗动脉粥样硬化的机制,并提供了克服药物递送障碍的系统策略。最后,我们讨论了基于β-CD的纳米组装体作为管理动脉粥样硬化和解决心血管疾病的新疗法的开发和应用中的当前障碍和潜在机会。
Atherosclerosis, a chronic and progressive condition characterized by the accumulation of inflammatory cells and lipids within artery walls, remains a leading cause of cardiovascular diseases globally. Despite considerable advancements in drug therapeutic strategies aimed at managing atherosclerosis, more effective treatment options for atherosclerosis are still warranted. In this pursuit, the emergence of β-cyclodextrin (β-CD) as a promising therapeutic agent offers a novel therapeutic approach to drug delivery targeting atherosclerosis. The hydrophobic cavity of β-CD facilitates its role as a carrier, enabling the encapsulation and delivery of various therapeutic compounds to affected sites within the vasculature. Notably, β-CD-based
nanoassemblies possess the ability to reduce cholesterol levels, mitigate inflammation, solubilize hydrophobic drugs and deliver drugs to affected tissues, making these nanocomponents promising candidates for atherosclerosis management. This review focuses on three major classes of β-CD-based
nanoassemblies, including β-CD derivatives-based, β-CD/polymer conjugates-based and polymer β-CD-based
nanoassemblies, highlighting a variety of formulations and assembly methods to improve drug delivery and therapeutic efficacy. These β-CD-based
nanoassemblies exhibit a variety of therapeutic mechanisms for atherosclerosis and offer systematic strategies for overcoming barriers to drug delivery. Finally, we discuss the present obstacles and potential opportunities in the development and application of β-CD-based
nanoassemblies as novel therapeutics for managing atherosclerosis and addressing cardiovascular diseases.